AOD-9604 Regret, Stopping, and Restarting: What Women Actually Experience

What AOD-9604 Actually Is (and Is Not)

AOD-9604 is a synthetic fragment of human growth hormone, specifically amino acids 176 through 191 of the GH molecule. It does not bind the GH receptor the same way intact GH does. The theory behind its use for fat loss is that this fragment retains the lipolytic activity of GH without the insulin-desensitizing effects of full-length growth hormone.

That distinction matters to you as a woman. Full-length recombinant GH is associated with fluid retention, carpal tunnel, and worsening insulin resistance, effects that are particularly unwelcome if you have PCOS or are in perimenopause, when insulin sensitivity already tends to decline. AOD-9604, at least in early-phase data, did not produce those effects at 500 mcg daily in the METAOD-001 trial.

What the Trial Data Actually Shows

The primary human evidence comes from a small, industry-sponsored trial published in 2001. In that study, participants receiving 500 mcg of AOD-9604 subcutaneously daily lost statistically more fat mass than placebo over 12 weeks. The effect size was modest. A subsequent larger phase 2 program was halted; no phase 3 trial has been completed.

The trial enrolled predominantly men or mixed-sex cohorts. Female-specific pharmacokinetic data, meaning how a woman's body absorbs, distributes, and clears the peptide across her cycle or across menopause, does not exist in the published literature. This is a real evidence gap, not a minor footnote.

Why Women Use It Anyway

Despite the thin evidence, women turn to AOD-9604 for several specific reasons. Perimenopausal fat redistribution to the abdomen, PCOS-related insulin resistance that blunts fat loss, and post-menopausal metabolic slowdown all create a gap between effort and result that can feel desperate. The peptide's reputation for targeting visceral fat, whether or not that is proven in women, makes it appealing precisely to the women who most need caution.

Real Women's Experiences: Regret, Reddit, and What the Reviews Actually Say

Online reviews of AOD-9604 cluster into three distinct sentiment groups, a pattern consistent across Reddit communities, Drugs.com user reports, and Trustpilot entries. Understanding which group you are in shapes whether stopping was a mistake and whether restarting makes sense.

Group 1: "I Stopped Too Early" (The Most Common Regret Pattern)

The most common regret pattern involves women who stopped AOD-9604 between weeks 3 and 6, before most users report noticing any body composition change. Posts in r/Peptides and r/PeptidesForWomen frequently describe this arc: injection site irritation or mild nausea in the first two weeks leads to discontinuation, followed by disappointment when weight loss does not occur, and eventual regret when other users describe results appearing at weeks 8 to 12.

This is clinically plausible. Even in the METAOD-001 data, fat mass changes were measured over 12 weeks, not 4. Stopping at week 4 is stopping before the window the trial used to detect any effect.

If this is your situation, restarting is a legitimate consideration, but only after addressing why you stopped. If the reason was injection site discomfort, rotating sites or adjusting reconstitution dilution resolves most cases. If the reason was gastrointestinal symptoms, those typically resolve by week 3.

Group 2: "I Used It, Saw Results, Stopped, and Regained" (Dependency Concern)

A second group describes clear fat loss during use, often 3 to 6 pounds over 10 to 14 weeks, followed by gradual regain after stopping. This pattern is consistent with any intervention that addresses a physiological driver of fat accumulation without permanently changing the underlying driver.

For perimenopausal and post-menopausal women, the underlying driver is estrogen decline, which shifts fat storage toward visceral and central depots. Estrogen decline accelerates visceral fat accumulation, a pattern documented in the Study of Women's Health Across the Nation (SWAN). AOD-9604 does not change estrogen status. If that is the root cause of your fat redistribution, stopping the peptide removes the only active tool, and regain follows.

The regret in this group is less about the decision to stop and more about the absence of a maintenance plan. Restarting without addressing hormone status, sleep, or dietary pattern is likely to produce the same cycle.

Group 3: "It Never Worked and I Wish I Had Not Started" (True Regret)

A smaller but real group reports no effect after 12 or more weeks and describes the regret of cost, needle burden, and emotional investment in a compound that produced nothing measurable. This group's experience is also clinically coherent. Human growth hormone responses vary substantially between individuals, and there is no validated predictor of who will respond to GH-axis peptides. Women with already-suppressed IGF-1 from chronic caloric restriction, women with untreated hypothyroidism (a common co-diagnosis in women reporting weight difficulty), or women on hormonal contraception that alters GH pulsatility may all be less likely to respond.

Before restarting after a non-response, a workup for thyroid function, cortisol, and hormonal status is worth having. Chasing a peptide response on top of an unaddressed thyroid or cortisol problem is not a good use of money or time.

Stopping AOD-9604: Is There a Right Way to Do It?

No taper protocol is established in any published guideline. AOD-9604 does not cause physical dependence in the way that exogenous growth hormone does after long-term use. You will not experience a clinical withdrawal syndrome if you stop abruptly.

What You May Notice After Stopping

The most consistently reported post-discontinuation experiences, across Reddit and Drugs.com user comments, are:

• Return of appetite to pre-treatment levels, sometimes described as feeling more hungry than before starting
• Gradual weight regain starting around weeks 4 to 8 after stopping
• No hormonal symptoms directly attributable to discontinuation

The appetite observation is worth taking seriously. AOD-9604 may have some interaction with leptin signaling pathways, at least in animal models. In rodent studies, the HGH 176-191 fragment reduced food intake as well as fat mass. Whether this translates to appetite regulation in women is not established, but it is a plausible mechanism for why some women feel hungrier after stopping.

Life-Stage Considerations for Stopping

Reproductive years: If you stopped because you are planning to conceive or recently found out you are pregnant, that was the right call. See the pregnancy section below for detail.

Perimenopause: This is when many women first start AOD-9604. Stopping without addressing the underlying hormonal shift means the fat redistribution continues unopposed. A conversation with your clinician about menopausal hormone therapy (MHT) is warranted before you restart a peptide.

Post-menopause: The same hormonal context applies. Menopausal hormone therapy, particularly estradiol, is associated with reduced visceral fat accumulation in post-menopausal women. Addressing estrogen status may reduce your reliance on a compound with limited evidence.

Restarting AOD-9604: What to Consider Before You Do

Restarting is not inherently dangerous based on available data. No published study has examined repeat cycles, so the evidence base for restart protocols is entirely absent. What follows is a framework for thinking through the decision, not a clinical protocol.

Questions to Answer Before Restarting

1. Why did you stop? If it was side effects, have you resolved the cause? If it was cost, has your financial situation changed? If it was lack of results, have you investigated why?

2. What has changed in your hormonal or metabolic context? A woman who stopped at 38 and is restarting at 41 may be in a different hormonal environment entirely, one where thyroid or perimenopausal factors now dominate.

3. What is your source? Peptide quality is not regulated. The FDA has issued warnings about peptide compounders and unapproved injections, and purity varies significantly between suppliers. Restarting with a low-quality product carries infection and contamination risk.

4. Are you combining with other compounds? Women in online communities sometimes restart AOD-9604 alongside semaglutide or tirzepatide. There is no interaction data for this combination, and the additive effects on appetite and fat metabolism are entirely unknown.

Dose on Restart

The dose most commonly described in structured peptide programs is 500 mcg subcutaneously once daily, taken 30 minutes before the first meal or before exercise, which mirrors the METAOD-001 protocol. Some compounding pharmacy protocols use 250 mcg twice daily on the premise of more stable plasma levels, but no comparative data supports one schedule over the other.

Starting at a lower dose on restart (250 mcg daily for the first two weeks) to reassess tolerability is a reasonable and cautious approach, particularly if your previous stop was driven by side effects.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

AOD-9604 is not safe in pregnancy and should not be used during breastfeeding. This is not a theoretical caution. It is the only appropriate position given the complete absence of human gestational safety data.

Pregnancy

No human pregnancy data exists for AOD-9604. The compound has not been assigned an FDA pregnancy category because it has never been approved as a drug. Animal reproductive toxicology studies have not been published in accessible, peer-reviewed literature. The FDA's standard position for investigational compounds with no gestational safety data is to avoid use in pregnancy.

GH axis manipulation during pregnancy carries theoretical risk. Growth hormone and its signaling pathways play a role in placental development and fetal growth. Introducing a synthetic GH fragment during organogenesis or any stage of pregnancy cannot be considered safe without data.

If you are trying to conceive, stop AOD-9604 before your first active conception cycle. Given the absence of half-life data in women, a minimum washout of 4 weeks is a conservative and sensible precaution, though no evidence-based washout period exists.

If you discover you are pregnant while using AOD-9604, stop immediately and inform your obstetric provider. Do not restart until after delivery and after you have completed breastfeeding.

Lactation

No data exists on transfer of AOD-9604 into breast milk. Peptides are generally partially degraded in the infant gastrointestinal tract, which is sometimes cited as a reason for reassurance. That reasoning is insufficient when no transfer data exists. The LactMed database maintained by NIH lists no entry for AOD-9604, reflecting the absence of any lactation pharmacokinetic study.

Avoid AOD-9604 entirely during breastfeeding.

Contraception

If you are sexually active and using AOD-9604, use reliable contraception. Because this compound targets GH axis signaling and may interact with metabolic hormones relevant to the menstrual cycle, unplanned pregnancy during use should be avoided. Combined oral contraceptives alter GH pulsatility, which is a potential interaction that has not been studied.

Who AOD-9604 Is and Is Not Right For, by Life Stage

May Be a Consideration For

• Perimenopausal women experiencing visceral fat accumulation resistant to diet and exercise, who have already optimized thyroid and hormonal status and are looking for adjunct approaches
• Women with PCOS in the reproductive years who have addressed insulin resistance through first-line measures (metformin, inositol, diet) but continue to struggle with central fat
• Post-menopausal women not eligible for MHT who have documented visceral fat concerns and understand the evidence limitations

Not Appropriate For

• Women trying to conceive, currently pregnant, or breastfeeding (see above)
• Women with active malignancy, particularly hormone-sensitive cancers, given theoretical GH axis effects
• Women with untreated hypothyroidism or uncontrolled cortisol excess, where the underlying condition needs to be addressed first
• Women expecting rapid results, given the 8 to 12 week minimum before any meaningful assessment is possible
• Women sourcing peptides from unverified online vendors, where sterility and purity cannot be confirmed

Does AOD-9604 Work for Everyone?

No. It does not. The honest answer is that the responder profile for this compound is not defined in any published study, and the primary evidence base is thin and outdated.

A 2021 systematic review of GH secretagogues and GH fragments for body composition found insufficient evidence to support clinical use in any population. That conclusion has not changed because no large-scale trial has been completed since the early-phase METAOD-001 work.

Women with strong endogenous GH pulsatility, younger reproductive-age women with good sleep and no significant hormonal disruption, may see less benefit than women whose GH axis is already blunted by age, menopause, or chronic stress. Paradoxically, those in whom GH axis activity is most suppressed (which includes many perimenopausal and post-menopausal women) may theoretically respond more, but may also carry more cardiovascular and metabolic context that warrants caution with any unregulated compound.

The trial data, such as it is, showed a statistically significant but modest fat mass reduction of approximately 1.4 kg over 12 weeks at the 500 mcg dose in the METAOD-001 trial. For context, semaglutide 2.4 mg weekly produced 15.9% mean body weight reduction over 68 weeks in the STEP 1 trial, a population that included 75% women. These are not competing options in the same evidence tier.

Sex-Specific Physiology: Why This Peptide Behaves Differently in Women

Growth hormone secretion is not the same in men and women. Women have higher GH pulse amplitude and more frequent GH pulses than age-matched men, a pattern that changes substantially with menopause. Estrogen modulates GH secretion by increasing GH pulse frequency, which is one reason post-menopausal women experience a disproportionate decline in GH axis activity as estrogen falls.

This has two practical implications. First, the dose of AOD-9604 established in a male-dominant or mixed-sex trial may not be the optimal dose for a post-menopausal woman with a different baseline GH pulse pattern. Second, women on estrogen-containing MHT may have a meaningfully different pharmacodynamic response than women who are not, because estrogen itself is modulating the axis the peptide is targeting.

Neither scenario has been studied. These are gaps in the evidence, not reassurances that the compound is safe and effective for you in your current hormonal state.

The menstrual cycle also alters GH secretion. GH pulse amplitude is highest in the late follicular phase. Whether timing AOD-9604 dosing to the follicular phase would improve response in reproductive-age women is entirely speculative, but it is the kind of question that a well-designed women's-specific trial would answer. That trial has not been done.

A Practical Framework for Women Considering Restarting

Before you inject again, work through this sequence with your prescribing provider or a women's health NP:

1. Get baseline labs. TSH, free T4, fasting insulin, fasting glucose, IGF-1, and estradiol if perimenopausal or post-menopausal. These establish whether a non-response had an identifiable cause.

2. Confirm your source and the peptide's purity. Ask for a certificate of analysis from the compounding pharmacy. Reconstituted peptides require bacteriostatic water and sterile syringes. Do not restart with a product you cannot verify.

3. Set a 12-week minimum evaluation window. Stopping at week 6 because you do not see results is the most common regret. If you restart, commit to the full window.

4. Define what "working" means before you start. A specific, measurable outcome (DEXA-measured fat mass, waist circumference, fasting insulin) is more useful than "feeling better" as a decision criterion.

5. Build the non-peptide foundation. Resistance training 2 to 3 times weekly is associated with meaningful preservation of lean mass in perimenopausal women. Protein intake of at least 1.2 g per kg body weight supports that. AOD-9604 on top of a weak foundation will produce weak results.

Your prescribing provider should document a rationale for use and a discontinuation plan before you begin. If they cannot explain what success looks like and when you would stop, that is information worth having before you start injecting.